DocGo Inc. (DCGO) SEC Filings & Earnings Calls
EquiReason read 15 DocGo Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-05 — DocGo entered a new credit agreement (term loan and revolving credit facility), terminated existing revolving credit facility, and issued unregistered shares. Also entered a consul.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 26.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
5 Oct 20268-K · 1.01, 1.02, 2.03, 3.02, 8.01DocGo entered a new credit agreement (term loan and revolving credit facility), terminated existing revolving credit facility, and issued unregistered shares. Also entered a consulting services agreement to manage Hicuity's non-clinical opeopen
Figures in the filing · each found in the filing text
| Term loan facility principal amount | $150M | |
| Revolving credit facility principal amount | $50M |
Risks flagged
New debt financing increases leverage; termination of existing facility may indicate restructuring of debt obligations.
“entered into a Credit Agreement... providing for a term loan facility in an aggregate principal amount of $150.0 million and a revolving credit facility in an aggregate principal amount of $50.0 million”
Issuance of unregistered shares dilutes existing shareholders.
“Item 3.02 Unregistered Sales of Equity Securities.” · word for word
17 Aug 202610-QDocGo entered into a merger agreement to acquire Hicuity Health, a tele-critical care provider, with stock consideration and assumed debt.acquisitionopen
Risks flagged
Nasdaq Delisting Risk
“On January 26, 2026, the Company received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that, based upon the closing bid price of the Common Stock from December 9, 2025 to January 23, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2)” · word for word
Government Contract Concentration Risk
“While the Company’s government contract work declined in 2025 and for the three and six months ended June 30, 2026, both in absolute dollar terms and as a percentage of overall consolidated revenue, due primarily to the ending of large migrant-related projects in New York”
Litigation Risk
“The parties reached an agreement to settle the action for an amount of $ 12,500,000 (covered by the Company’s insurance policy, subject to retention)” · word for word
17 Aug 20268-K · 1.01, 2.02Q2 2026 revenue $73.4M down 9% YoY; net loss $18.0M; adjusted EBITDA -$6.3M; guidance cut: FY2026 adjusted EBITDA lowered to -$17 to -$22M from -$5 to -$10M.open
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $73M | -9% y/y |
| GAAP gross margin · Q2-2026 | 26.9% | |
| Adjusted gross margin · Q2-2026 | 30.5% | |
| Net income · Q2-2026 | $-18M | |
| Adjusted EBITDA · Q2-2026 | $-6M | |
| Medical Transportation Services revenue · Medical Transportation Services · Q2-2026 | $52M | +5% y/y |
| Mobile Health Services revenue · Mobile Health Services · Q2-2026 | $21M | -31% y/y |
| Cash and cash equivalents · Q2-2026 | $48M | |
| Unrestricted cash · Q2-2026 | $25M |
Guidance
FY2026 adjusted EBITDA guidance cut from -$5 to -$10M to -$17 to -$22M; revenue guidance narrowed to $305-310M from $300-315M
Adjusted EBITDA guidance cut sharply; revenue guidance narrowed slightly; management expects to exit year at profitable run rate.
Risks flagged
Significant adjusted EBITDA guidance cut indicates worsening profitability outlook.
“FY2026 adjusted EBITDA guidance lowered to -$17 to -$22M from -$5 to -$10M.”
Cash burn continues; unrestricted cash declined $10.5M in quarter.
“Unrestricted cash $25.2M vs $35.7M prior quarter.”
31 Jul 20268-K · 3.01Nasdaq granted DocGo additional 180 days to Jan 25, 2027 to regain minimum bid price compliance; stockholder-approved reverse stock split authorized but not yet implemented; compliance not assured.open
Risks flagged
Delisting risk if minimum bid price not regained by Jan 25, 2027
“Nasdaq letter; reverse stock split authorized but not yet implemented; no assurance of compliance.”
2 Jul 20268-K · 7.01Board extended share repurchase program expiration from June 30, 2026 to December 31, 2026; no other changes. Program allows up to $26M in repurchases.open
Figures in the filing · each found in the filing text
| repurchase authorization · 2026-06-26 | $26M |
11 May 202610-QDocGo reported a decline in government contract revenue and received a Nasdaq non-compliance notice.open
Figures in the filing · each found in the filing text
| Interest expense, net · Q1-2026 | $-99732.00 | |
| Loss on change in fair value of contingent consideration · Q1-2026 | $3M | |
| Insurance proceeds · Q1-2026 | $5M |
Risks flagged
Nasdaq delisting risk
“On January 26, 2026, the Company received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that, based upon the closing bid price of the Common Stock from December 9, 2025 to January 23, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid” · word for word
Government contract concentration and decline
“While the Company’s government contract work declined in 2025 and for the three months ended March 31, 2026, both in absolute dollar terms and as a percentage of overall consolidated revenue, due primarily to the ending of large migrant-related projects in New York, the Company continues to bid on government contracts and expects some revenue from this secto” · word for word
Litigation and regulatory risk
“The parties reached an agreement to settle the action for an amount of $ 12,500,000 (covered by the Company’s insurance policy, subject to retention), and on March 24, 2026, the court approved the settlement.” · word for word
11 May 20268-K · 2.02DocGo raises full-year 2026 revenue guidance to $300-$315M from $290-$310M, citing strong demand for virtual care services. Q1 revenue $75.6M (ex-migrant programs +19.3%). Adjusted EBITDA guidance unchanged at ($5-$10)M. Margin pressure froopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $76M | -21% y/y |
| Revenue excluding migrant-related programs · Q1-2026 | $76M | +19% y/y |
| GAAP gross margin · Q1-2026 | 28.1% | |
| Adjusted gross margin · Q1-2026 | 31.6% | |
| Net income · Q1-2026 | $-17M | +50% y/y |
| Adjusted EBITDA · Q1-2026 | $-10M | +162% y/y |
| Medical Transportation Services revenue · Medical Transportation Services · Q1-2026 | $52M | +2% y/y |
| Mobile Health Services revenue · Mobile Health Services · Q1-2026 | $24M | -48% y/y |
| Cash and cash equivalents including restricted cash and investments · Q1-2026 | $60M |
Guidance
Revenue guidance raised to $300-$315M from $290-$310M (midpoint +$7.5M)
Revenue guidance raised on strong virtual care demand; adjusted EBITDA guidance unchanged; margin pressure from hiring and fuel costs.
Risks flagged
Margin pressure from hiring and fuel cost increases; fuel cost sensitivity due to Middle East conflict.
“CFO: 'meaningful negative impact from the increase in fuel prices caused by the war in the Middle East.'”
Negative adjusted EBITDA and net loss; cash burn continues.
“Adjusted EBITDA ($10.2)M; net loss ($16.7)M; cash decreased from $68.3M to $59.9M.”
22 Apr 20268-K · 5.02DocGo Inc. filed an 8-K reporting the departure of director Stephen K. Klasko, appointment of Michael Burdiek as independent Chair, and formation of a special committee for cost reduction. No disagreement cited.open
Risks flagged
Board changes may indicate strategic shift or governance concerns.
“Director departure and formation of cost reduction committee.”
22 Apr 2026DEF 14AProxy statement proposing reverse stock split to regain Nasdaq compliance, with significant negative financial performance and governance changes.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $322M | |
| Cash provided by operating activities · FY2025 | $35M | |
| Net income (loss) · FY2025 | $-196M | |
| Total Stockholder Return (TSR) · FY2025 | $12.00 | |
| Compensation Actually Paid to CEO · FY2025 | $-1M | |
| Average Compensation Actually Paid to Non-PEO NEOs · FY2025 | $131021.00 | |
| Shares outstanding · 2026-04-20 | 98,778,413 | |
| Stock price · 2026-04-01 | $0.57 |
Risks flagged
Nasdaq delisting risk
“On January 26, 2026, the Company received a letter from the Staff of Nasdaq notifying the Company that, based upon the closing bid price of the Company's common stock from December 9, 2025 to January 23, 2026, the Company is not currently in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of $1.00 pe” · word for word
Reverse stock split may not cure deficiency; new Nasdaq rules limit split use
“On January 15, 2025, the SEC approved an amendment to the Nasdaq listing rules which limit the conditions under which a listed company can use a reverse stock split to meet the Minimum Bid Requirement. In particular, the amendment provides that if a company executes a reverse stock split to regain compliance with the Minimum Bid Requirement but its stock pri” · word for word
Massive net loss and negative shareholder return
“Net (Loss) Income: ($196,367,155) for 2025; Total Stockholder Return: $12 per $100 investment.”
CEO compensation actually paid deeply negative
“Compensation Actually Paid to PEO $ (1,137,929) for 2025.” · word for word
Litigation risk from shareholder lawsuit over corporate opportunity waiver
“On March 4, 2024, a purported stockholder of the Company, John McDonald, filed a putative class action complaint in the Court of Chancery of the State of Delaware against the Company and the members of the Board of Directors, alleging, among other things, that the Existing Corporate Opportunity Provision violates Delaware law.” · word for word
16 Mar 202610-KLabor costs increased to 77% of revenue; net capital expenditures $4.3M; federal NOLs increased to $47.1M.earningsopen
Figures in the filing · each found in the filing text
| Labor costs as percentage of revenue · FY2025 | 77.0% | |
| Net capital expenditures · FY2025 | $4M | +30% y/y |
| Federal net operating loss carryforwards · FY2025 | $47M |
Risks flagged
Labor cost pressure
“Labor expenses (which includes both directly employed personnel as well as subcontracted labor) are DocGo’s largest cost, representing approximately 77%, 68% and 73% of its 2025, 2024 and 2023 revenues, respectively.” · word for word
Going concern risk
“If DocGo is unable to fund its liquidity needs, DocGo will not be able to continue to operate its business pursuant to its current business plan.” · word for word
NOL limitation risk
“If DocGo undergoes an 'ownership change' under Section 382 of the Internal Revenue Code... DocGo’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset future taxable income or taxes may be limited.” · word for word
16 Mar 20268-K · 2.02DocGo Q4 2025 revenue $74.9M vs $120.8M YoY; net loss $142.3M vs $7.6M loss; adjusted EBITDA loss $11.3M vs $1.1M profit; impairments $78M; raises 2026 guidance; explores strategic alternatives.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q4-2025 | $75M | -38% y/y |
| GAAP gross margin · Q4-2025 | 27.2% | |
| Adjusted gross margin · Q4-2025 | 32.5% | |
| Net loss · Q4-2025 | $-142M | +1772% y/y |
| Adjusted EBITDA · Q4-2025 | $-11M | -1127% y/y |
| Medical Transportation Services revenue · Medical Transportation Services · Q4-2025 | $50M | +2% y/y |
| Mobile Health Services revenue · Mobile Health Services · Q4-2025 | $25M | -65% y/y |
| Cash and cash equivalents · 2025-12-31 | $68M | |
| Full year total revenue · FY2025 | $322M | -48% y/y |
| Full year net loss · FY2025 | $-196M | -1566% y/y |
Guidance
2026 revenue and adjusted EBITDA guidance raised due to customer expansions, improved EMS hiring rates and efficiency initiatives
Company raises 2026 guidance citing customer expansions and operational improvements, despite Q4 2025 earnings miss and impairments.
Risks flagged
Migrant program wind-down causes significant revenue decline and earnings miss
“Revenue decline entirely due to wind-down of migrant-related programs, which generated $7.4M in Q4 2025 vs $60.2M in Q4 2024.”
Large non-cash impairments and net loss raise going concern risk
“Impairments of $78M and net loss of $142.3M in Q4 2025.”
Cash burn and declining cash reserves
“Cash decreased from $95.2M (Sep 30, 2025) to $68.3M (Dec 31, 2025), including $12.5M acquisition cost.”
10 Nov 20258-K · 2.02DocGo Q3 2025 revenue $70.8M vs $138.7M YoY, net loss $29.7M vs income $4.5M, adjusted EBITDA loss $7.2M vs $17.9M; core revenue up 8% ex-migrant; guides FY25 rev $315-320M, adj EBITDA loss $25-28M; FY26 rev $280-300M, adj EBITDA loss $15-2earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $71M | -49% y/y |
| GAAP gross margin · Q3-2025 | 20.0% | |
| Adjusted gross margin · Q3-2025 | 33.0% | |
| Net income (loss) · Q3-2025 | $-30M | -760% y/y |
| Adjusted EBITDA · Q3-2025 | $-7M | -140% y/y |
| Transportation Services revenue · Transportation Services · Q3-2025 | $50M | +4% y/y |
| Mobile Health Services revenue · Mobile Health Services · Q3-2025 | $21M | -77% y/y |
| Cash and cash equivalents (including restricted cash and investments) · Q3-2025 | $95M | -26% y/y |
| Cash flow from operations · Q3-2025 | $2M |
Guidance
FY25 revenue $315-320M (prior $300-330M); FY25 adjusted EBITDA loss $25-28M (prior loss $20-30M); FY26 revenue $280-300M; FY26 adjusted EBITDA loss $15-25M.
FY25 guidance narrowed; FY26 initial guidance shows revenue decline but narrower EBITDA loss; management emphasizes core growth and strategic investments.
Risks flagged
Migrant program wind-down creates significant revenue and earnings headwind; core business growth may not fully offset.
“Revenue decline entirely due to wind-down of migrant-related programs, which generated $8.4M in Q3 2025 vs $80.7M in Q3 2024.”
Non-cash impairments of $16.7M indicate potential overpayment for past acquisitions or asset devaluation.
“Included in this quarter’s loss was a total of $16.7 million of non-cash impairments of intangible assets and goodwill.” · word for word
Negative adjusted EBITDA and net loss raise concerns about profitability trajectory.
“Adjusted EBITDA loss was $7.2 million for Q3 2025, compared to adjusted EBITDA of $17.9 million for Q3 2024.”
10 Nov 202510-QDocGo reported a net loss of $29.7M vs net income of $4.5M a year ago, with revenue down 49% due to migrant project wind-down and $16.7M in impairment charges.open
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $71M | -49% y/y |
| Mobile Health Services Revenue · Mobile Health Services · Q3-2025 | $21M | -77% y/y |
| Transportation Services Revenue · Transportation Services · Q3-2025 | $50M | +4% y/y |
| Net Income (Loss) · Q3-2025 | $-30M | |
| Cash and Cash Equivalents · 2025-09-30 | $73M | |
| Accounts Receivable, net · 2025-09-30 | $107M | |
| Goodwill Impairment · Mobile Health Services · Q3-2025 | $9M | |
| Intangible Asset Impairment · Mobile Health Services · Q3-2025 | $8M | |
| U.S. Trip Volume · Transportation Services · Q3-2025 | 71,541 | +3% y/y |
| Average Trip Price · Transportation Services · Q3-2025 | $411.00 | +2% y/y |
Guidance
Mobile Health Services revenues expected to be lower in 2026 than 2025
Management explicitly guided that Mobile Health Services revenues will be lower in 2026 than 2025 due to the absence of migrant-related project revenues.
Risks flagged
Revenue Concentration on Government Contracts
“The Company had one customer that accounted for approximately 37% of revenues for the nine months ended September 30, 2025.” · word for word
Further Impairment Risk
“Additional impairments of the carrying value of our goodwill or other intangible assets could adversely affect our financial condition and results of operations.” · word for word
Mobile Health Services Segment Decline
“we expect that overall Mobile Health Services revenues will be lower in 2026 than they were in 2025, given the absence of migrant-related project revenues.” · word for word
Margin Compression
“Cost of revenues as a percentage of revenues increased to 74.4% in the three months ended September 30, 2025 from 64.0% in the three months ended September 30, 2024.” · word for word
DocGo Inc. — questions
- What did DocGo Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-10-05 — DocGo entered a new credit agreement (term loan and revolving credit facility), terminated existing revolving credit facility, and issued unregistered shares. Also entered a consulting services agreement to manage Hicuity's non-clinical ope
Every figure on this page comes from DocGo Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.